Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, Chiara Brando, Valerio Gristina, Daniela Cancelliere, Alessia Pivetti, Silvia Contino, Emilia Di Giovanni, Nadia Barraco, Marco Bono, Ambra Giurintano, Tancredi Didier Bazan Russo, Andrea Gottardo, Sofia Cutaia, Erika Pedone, Marta Peri, Lidia Rita Corsini, Daniele Fanale, Antonio Galvano, Giovanni Scambia, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan
Breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) deleterious variants were the first and, still today, the main biomarkers of poly(ADP)ribose polymerase (PARP)-inhibitors (PARPis) benefit. The recent, increased, numbers of individuals referred for counseling and multigene panel testing, and the remarkable expansion of approved PARPis, not restricted to BRCA1/BRCA2-Pathogenic Variants (PVs), produced a strong clinical need for non-BRCA biomarkers. Significant limitations of the current testing and assays exist...
December 2023: Cancer Treatment Reviews